Ceramide-mediated Insulin Resistance and Impairment of Cognitive-motor Functions

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2010 Aug 10

PMID 20693650

Citations 55

Authors

Suzanne M de la Monte

Ming Tong

Vananh Nguyen

Mashiko Setshedi

Lisa Longato

Jack R Wands

Affiliations

Soon will be listed here.

Abstract

Obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH) are associated with cognitive impairment, brain insulin resistance, and neurodegeneration. Recent studies linked these effects to increased pro-ceramide gene expression in liver and increased ceramide levels in serum. Since ceramides are neurotoxic and cause insulin resistance, we directly examined the role of ceramides as mediators of impaired signaling and central nervous system function using an in vivo model. Long Evans rat pups were administered C2Cer:N-acetylsphinganine or its inactive dihydroceramide analog (C2DCer) by i.p. injection. Rats were subjected to rotarod and Morris water maze tests of motor and cognitive function, and livers and brains were examined for histopathology and integrity of insulin/IGF signaling. C2Cer treatment caused hyperglycemia, hyperlipidemia, and mild steatohepatitis, reduced brain lipid content, and increased ceramide levels in liver, brain, and serum. Quantitative RT-PCR analysis revealed significant alterations in expression of several genes needed for insulin and IGF-I signaling, and multiplex ELISAs demonstrated inhibition of signaling through the insulin or IGF-1 receptors, IRS-1, and Akt in both liver and brain. Ultimately, the toxic ceramides generated in peripheral sources such as liver or adipose tissue caused sustained impairments in neuro-cognitive function and insulin/IGF signaling needed for neuronal survival, plasticity, and myelin maintenance in the brain. These findings support our hypothesis that a liver/peripheral tissue-brain axis of neurodegeneration, effectuated by increased toxic lipid/ceramide production and transport across the blood-brain barrier, could mediate cognitive impairment in T2DM and NASH.

Citing Articles

Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.

Ahlawat A, Walia V, Garg M Acta Neurol Belg. 2025; .

PMID: 39762668 DOI: 10.1007/s13760-024-02706-7.

A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer's disease, and their co-morbidities.

Pan Y, Li J, Lin P, Wan L, Qu Y, Cao L Front Pharmacol. 2024; 15:1348410.

PMID: 38379904 PMC: 10877008. DOI: 10.3389/fphar.2024.1348410.

The relevance between abnormally elevated serum ceramide and cognitive impairment in Alzheimer's disease model mice and its mechanism.

Liu X, Jin Y, Cheng X, Song Q, Wang Y, He L Psychopharmacology (Berl). 2024; 241(3):525-542.

PMID: 38277004 DOI: 10.1007/s00213-024-06530-y.

Aerobic exercise combined with memory strategy training improve the cognitive function.

Zhao N, Yao X, Wang Y, Chen X, Wang Z Brain Behav. 2023; 13(11):e3234.

PMID: 37612254 PMC: 10636400. DOI: 10.1002/brb3.3234.

Type 2 Diabetes and Alzheimer's Disease: The Emerging Role of Cellular Lipotoxicity.

Marrano N, Biondi G, Borrelli A, Rella M, Zambetta T, Di Gioia L Biomolecules. 2023; 13(1).

PMID: 36671568 PMC: 9855893. DOI: 10.3390/biom13010183.

References

Mizutani Y, Kihara A, Igarashi Y . Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 2005; 390(Pt 1):263-71. PMC: 1184580. DOI: 10.1042/BJ20050291. View

Tong M, Neusner A, Longato L, Lawton M, Wands J, de la Monte S . Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis. 2010; 17(4):827-44. PMC: 2952429. View

Cantarini M, de la Monte S, Pang M, Tong M, DErrico A, Trevisani F . Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006; 44(2):446-57. DOI: 10.1002/hep.21272. View

Morales V, Santana P, Diaz R, Tabraue C, Gallardo G, Blanco F . Intratesticular delivery of tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology. 2003; 144(11):4763-72. DOI: 10.1210/en.2003-0569. View

Ichinose Y, Eguchi K, Migita K, Kawabe Y, Tsukada T, Koji T . Apoptosis induction in synovial fibroblasts by ceramide: in vitro and in vivo effects. J Lab Clin Med. 1998; 131(5):410-6. DOI: 10.1016/s0022-2143(98)90141-x. View

Larner A . The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord. 1997; 8(4):203-9. DOI: 10.1159/000106632. View

Ikonomovic M, Mufson E, Wuu J, Cochran E, Bennett D, DeKosky S . Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003; 5(1):39-48. DOI: 10.3233/jad-2003-5106. View

Costantini C, Scrable H, Puglielli L . An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J. 2006; 25(9):1997-2006. PMC: 1456930. DOI: 10.1038/sj.emboj.7601062. View

Brugg B, Michel P, Agid Y, Ruberg M . Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem. 1996; 66(2):733-9. DOI: 10.1046/j.1471-4159.1996.66020733.x. View

10.

Rector R, Thyfault J, Wei Y, Ibdah J . Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008; 14(2):185-92. PMC: 2675112. DOI: 10.3748/wjg.14.185. View

11.

Craft S . Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006; 20(4):298-301. DOI: 10.1097/01.wad.0000213866.86934.7e. View

12.

Laviad E, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill Jr A . Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem. 2008; 283(9):5677-84. DOI: 10.1074/jbc.M707386200. View

13.

Satapathy S, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma B . Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99(10):1946-52. DOI: 10.1111/j.1572-0241.2004.40220.x. View

14.

Yalniz M, Bahcecioglu I, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu O . Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2007; 2006(6):34295. PMC: 1775029. DOI: 10.1155/MI/2006/34295. View

15.

Rosenberg P . Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry. 2006; 17(6):503-14. DOI: 10.1080/02646830500382037. View

16.

Friedrichs G, Swillo R, Jow B, Bridal T, Numann R, Warner L . Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia. J Cardiovasc Pharmacol. 2001; 39(1):18-28. DOI: 10.1097/00005344-200201000-00003. View

17.

Lester-Coll N, Rivera E, Soscia S, Doiron K, Wands J, de la Monte S . Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2006; 9(1):13-33. DOI: 10.3233/jad-2006-9102. View

18.

Spiegel S, Merrill Jr A . Sphingolipid metabolism and cell growth regulation. FASEB J. 1996; 10(12):1388-97. DOI: 10.1096/fasebj.10.12.8903509. View

19.

Haughey N, Steiner J, Nath A, McArthur J, Sacktor N, Pardo C . Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci. 2008; 13:5120-30. PMC: 2739118. DOI: 10.2741/3068. View

20.

Cole G, Neal J, Singhrao S, Jasani B, Newman G . The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis. Acta Neuropathol. 1993; 85(5):542-52. DOI: 10.1007/BF00230495. View